Cardio-Oncology

<p>Basic Concepts1. Current trends in cancer therapyMonica Mita2. Molecular Mechanisms Underlying Anthracycline Cardiotoxicity:Challenges in Cardio-OncologyLorrie Kirshenbaum3. Chemotherapy and cardiovascular biologyPaul A. Cahill4. AnthracyclinesEdward T H Yeh and Rohit Moudgil 5. Kinase inhibitors, ErbBs, VEGFAntonio Russo</p> <p>Recognition and Management 6. Role of novel imaging techniques in detection of chemotoxicity: cardiac MRI and nuclearLouise Elizabeth Jane Thomson7. Role of biomarkers in detecting cardiotoxicity (highly sensitive troponin, BNP)Daniela Cardinale8. Ischemic heart disease as a consequence of cancer therapyJoseph Carver9. Radiation and vascular complications (thrombosis, carotid atherosclerosis for head/neck cancer, Hodgkin’s lymphoma) [include valve and pericardium]Stephen Shiao10. Identification of at-risk patients and comorbidities that increase riskTochukwu Okwuosa11. Special considerations in pediatric patients and survivors of childhood cancerSteven Lipshultz and Vivian Franco 12. Special considerations of pre-mature menopause in women as a consequence of chemotherapyChrisandra Shufelt13. Cancer and ExerciseAhmed Al Badri14. Statin usage in cardio-oncology patientsSusmita Parashar15. Coordinating cardio-oncology careSusan Dent16. Role of coronary calcium, hs-CRP, ABIJanet Wei17. Hypertension and cancerAntoine Hage18. Pulmonary Hypertension and CancerAntoine Hage19. Detection of Cardiotoxicity by EchocardiographyStamatios Lerakis20. Cancer fatigue/chemo brain, rehabilitation and quality of life Arash Asher</p> <p>Managing the patient in advanced HF21. Management of advanced HF and transplant considerations in cancer patientsMichele A. Hamilton22. Heart transplant and LVADs in cancer survivors (role of immunosuppression in transplant patients)Michelle M. Kittleson23. QT prolongation, EP Devices to support the failing heart (ICDs, BiVs, Pacemakers) Mikhael El-Chami</p>